DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
פורמט:	Journal article
שפה:	English
יצא לאור:	Oxford University Press 2014

פריטים דומים

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
מאת: Gupta, A, et al.
יצא לאור: (2013)

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
מאת: Gupta, A, et al.
יצא לאור: (2020)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
מאת: Robert, C, et al.
יצא לאור: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
מאת: Robert, C, et al.
יצא לאור: (2013)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
מאת: Kirkwood, J, et al.
יצא לאור: (2012)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
מאת: Flaherty, K, et al.
יצא לאור: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
מאת: K. Haslett, et al.
יצא לאור: (2021-05-01)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
מאת: Edmund Poon, et al.
יצא לאור: (2017-08-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
מאת: Jessie Villanueva, et al.
יצא לאור: (2013-09-01)

Immunological effects of BRAF+MEK inhibition
מאת: Paolo A. Ascierto, et al.
יצא לאור: (2018-09-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
מאת: Eva Marie Erfurth, et al.
יצא לאור: (2024-12-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
מאת: Andrea Gazzin, et al.
יצא לאור: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
מאת: Tahar Sif eddine Bouchema, et al.
יצא לאור: (2022-11-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
מאת: Pacey, S, et al.
יצא לאור: (2016)

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
מאת: Anne L Estep, et al.
יצא לאור: (2007-12-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
מאת: Sara Bjursten, et al.
יצא לאור: (2019-11-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
מאת: Sarah J. Welsh, et al.
יצא לאור: (2015-03-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
מאת: Blessie Elizabeth Nelson, et al.
יצא לאור: (2023-05-01)

Effect of food on capsule and granule formulations of selumetinib
מאת: Sarit Cohen‐Rabbie, et al.
יצא לאור: (2022-04-01)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
מאת: Hui-Ju Huang, et al.
יצא לאור: (2021-06-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
מאת: Leijen, S, et al.
יצא לאור: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
מאת: Leijen, S, et al.
יצא לאור: (2011)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
מאת: Bengt Tholander, et al.
יצא לאור: (2020-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
מאת: Ken Saijo, et al.
יצא לאור: (2022-08-01)

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
מאת: Anaïs Roeser, et al.
יצא לאור: (2019-11-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
מאת: Lovisa Falkman, et al.
יצא לאור: (2024-04-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
מאת: Clare Judith Stones, et al.
יצא לאור: (2013-05-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
מאת: Jan Leipe, et al.
יצא לאור: (2019-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
מאת: Matthew R. Kroll, et al.
יצא לאור: (2024-07-01)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
מאת: Shivshankari Rajkumar, et al.
יצא לאור: (2022-04-01)

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
מאת: J. Steininger, et al.
יצא לאור: (2024-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
מאת: I. V. Samoylenko, et al.
יצא לאור: (2017-11-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
מאת: B. Ziółkowska, et al.
יצא לאור: (2024-01-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
מאת: Michael J. Vido, et al.
יצא לאור: (2018-11-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
מאת: Zeynep Eroglu, et al.
יצא לאור: (2016-01-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
מאת: Raphael Reinhard, MD, et al.
יצא לאור: (2018-03-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
מאת: Manrose Singh, et al.
יצא לאור: (2024-08-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
מאת: Sivakamavalli Jeyachandran
יצא לאור: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
מאת: Ariane Fizazi, et al.
יצא לאור: (2024-11-01)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
מאת: Marit A. C. Vermunt, et al.
יצא לאור: (2021-08-01)